The U.S. Food and Drug Administration approved Scynexis Inc.’s Brexafemme (ibrexafungerp tablets) as the first oral non-azole treatment for vaginal yeast infections.
Scynexis Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for oral ibrexafungerp for the treatment of vulvovaginal candidiasis.